Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 13
Partnerships 14
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 14
Amorfix Life Sciences Enters Into Co-Development Agreement With Trellis Bioscience 15
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 16
Equity Offering 17
ProMIS Neurosciences Raises USD5.6 Million in Private Placement of Shares and Warrants 17
ProMIS Neurosciences Raises USD1 Million in Second Tranche of Private Placement of Units 18
ProMIS Neurosciences Raises USD1.8 Million in First Tranche of Private Placement of Shares 20
ProMIS Neurosciences Raises USD0.4 Million in Private Placement of Units 21
ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 22
ProMIS Neurosciences Raises USD0.3 Million in Second and Final Tranche of Private Placement of Shares 23
ProMIS Neurosciences Raises USD0.5 Million in First Tranche of Private Placement of Shares 24
ProMIS Neurosciences to Raise Funds Through Rights Offering of Shares 25
ProMIS Neurosciences Raises USD0.77 million in Second and Final Tranche of Private Placement of Shares 26
Amorfix Life Sciences Raises USD1.2 Million in First Tranche of Private Placement of Shares 27
Amorfix Life Sciences Raises USD0.31 Million in Private Placement of Shares and Warrants 28
Amorfix Life Sciences Completes Third Tranche Of Private Placement Of Shares And Warrants For US$1 Million 29
Amorfix Life Sciences Completes Private Placement Of Securities For US$0.4 Million 30
Amorfix Life Sciences Completes Private Placement Of Units For US$0.5 Million 31
Amorfix Life Sciences Raises USD0.25 Million In a Private Placement Of Shares 32
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Shares For US$0.2 Million 33
Amorfix Life Sciences Completes First Tranche Of Private Placement Of Units For US$0.5 Million 34
Amorfix Life Sciences Completes Second And Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Amorfix Life Sciences Completes Private Placement Of Units For US$0.2 Million 36
Amorfix Life Sciences Completes Private Placement Of Units For US$1 Million 37
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For US$0.08 Million 38
Asset Transactions 40
Amorfix Life Sciences Plans to Divest its Assets 40
ProMIS Neurosciences Inc – Key Competitors 41
ProMIS Neurosciences Inc – Key Employees 42
ProMIS Neurosciences Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Aug 14, 2018: Promis Neurosciences reports second quarter 2018 financial results 44
May 11, 2018: ProMIS Neurosciences Announces First Quarter 2018 Results 46
Mar 14, 2018: ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results 48
Nov 13, 2017: ProMIS Neurosciences Announces Third Quarter 2017 Results 50
Aug 11, 2017: ProMIS Neurosciences Announces Second Quarter 2017 Results 52
Jul 10, 2017: ProMIS Neurosciences Provides Second Quarter Update for 2017 54
May 09, 2017: ProMIS Neurosciences Announces Q1 2017 Quarterly Results 55
Mar 30, 2017: ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation 56
Mar 15, 2017: ProMIS Neurosciences Announces Fiscal 2016 Annual Results 57
Corporate Communications 59
Sep 13, 2018: ProMIS Neurosciences appoints James Kupiec, MD as Chief Medical Officer 59
Dec 04, 2017: ProMIS Neurosciences Announces Trading on OTCQB Venture Market 60
Jun 06, 2017: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board 61
Mar 22, 2017: ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer 62
Mar 02, 2017: ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors 63
Government and Public Interest 64
May 31, 2017: ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia 64
Product News 65
10/11/2018: ProMIS Neurosciences identifies novel antibody drug candidates for Parkinsons Disease 65
09/28/2017: ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference 66
09/19/2017: ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease 67
09/13/2017: ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease 68
07/19/2017: ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer’s Disease Program 69
07/06/2017: ProMIS Neurosciences’ Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research 70
06/26/2018: ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases 71
05/24/2017: ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease 72
Apr 10, 2018: ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer’s Disease 73
03/28/2017: ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum 74
01/05/2017: ProMIS Neurosciences declares PMN 310 its first lead product for development in Alzheimer’s disease 75
Clinical Trials 76
Jan 23, 2018: ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies 76
Jan 04, 2018: ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies 77
Oct 17, 2017: ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease 78
Jul 05, 2017: ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017 79
Other Significant Developments 80
Aug 29, 2018: ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results 80
Oct 11, 2017: ProMIS Neurosciences Provides Third Quarter Update for 2017 81
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 13
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 14
Amorfix Life Sciences Enters Into Co-Development Agreement With Trellis Bioscience 15
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 16
ProMIS Neurosciences Raises USD5.6 Million in Private Placement of Shares and Warrants 17
ProMIS Neurosciences Raises USD1 Million in Second Tranche of Private Placement of Units 18
ProMIS Neurosciences Raises USD1.8 Million in First Tranche of Private Placement of Shares 20
ProMIS Neurosciences Raises USD0.4 Million in Private Placement of Units 21
ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 22
ProMIS Neurosciences Raises USD0.3 Million in Second and Final Tranche of Private Placement of Shares 23
ProMIS Neurosciences Raises USD0.5 Million in First Tranche of Private Placement of Shares 24
ProMIS Neurosciences to Raise Funds Through Rights Offering of Shares 25
ProMIS Neurosciences Raises USD0.77 million in Second and Final Tranche of Private Placement of Shares 26
Amorfix Life Sciences Raises USD1.2 Million in First Tranche of Private Placement of Shares 27
Amorfix Life Sciences Raises USD0.31 Million in Private Placement of Shares and Warrants 28
Amorfix Life Sciences Completes Third Tranche Of Private Placement Of Shares And Warrants For US$1 Million 29
Amorfix Life Sciences Completes Private Placement Of Securities For US$0.4 Million 30
Amorfix Life Sciences Completes Private Placement Of Units For US$0.5 Million 31
Amorfix Life Sciences Raises USD0.25 Million In a Private Placement Of Shares 32
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Shares For US$0.2 Million 33
Amorfix Life Sciences Completes First Tranche Of Private Placement Of Units For US$0.5 Million 34
Amorfix Life Sciences Completes Second And Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Amorfix Life Sciences Completes Private Placement Of Units For US$0.2 Million 36
Amorfix Life Sciences Completes Private Placement Of Units For US$1 Million 37
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For US$0.08 Million 38
Amorfix Life Sciences Plans to Divest its Assets 40
ProMIS Neurosciences Inc, Key Competitors 41
ProMIS Neurosciences Inc, Key Employees 42
ProMIS Neurosciences Inc, Subsidiaries 43
List of Figures
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10